Novel Coronavirus (SARS-CoV-2/COVID-19)
The Administration for Community Living July 1 at 2 p.m. ET will host a webinar featuring leaders sharing COVID19-related and other resources and research to help support older adults and persons with disabilities residing in rural communities.
The University of New Mexico School of Medicine’s Project ECHO July 2 will host at 12 p.m. ET a collaborative webinar on COVID-19’s treatment using dexamethasone and other steroids. Project ECHO (Extension for Community Healthcare Outcomes) is the university’s effort to demonopolize knowledge and…
SARS-CoV-2 infections may be 10 times higher than reported cases, according to new data from a Centers for Disease Control and Prevention partnership with commercial laboratories to test de-identified clinical blood specimens for antibodies in Connecticut, South Florida, the New York City area,…
The AHA outlined a number of actions Congress could take to help the nation prepare for the next pandemic, noting that the current pandemic also remains a challenge.
The Department of Health and Human Services announced an agreement with drug maker Gilead Sciences to allow U.S. hospitals to purchase up to 500,000 treatment courses of remdesivir through September, which HHS and state health departments will allocate as they did the previous 120,000 treatment…
“I just can’t imagine going back because people recognize the value of this.” That’s what Centers for Medicare & Medicaid Services Administrator Seema Verma said recently about the increased use of telehealth, signaling that doctoring from a distance — which has shown itself to be a lifesaving…
As many front-line health care workers move beyond the immediate pandemic crisis, now is the time to reflect on the psychological toll, writes Jesse Burgard, a regional chief mental health officer for the U.S. Department of Veterans Affairs and AHA Behavioral Health Services Council member.
The Food and Drug Administration added the AustinP51 emergency-use system to its list of ventilator authorized for emergency use in health care settings to treat adults during the COVID-19 pandemic.
A therapeutic, two-antibody COVID-19 treatment “cocktail” from Regeneron and the Biomedical Advanced Research and Development Authority moved to its first clinical trial, the developers earlier this month announced.
The Centers for Disease Control and Prevention has updated and expanded its list of people at risk of severe COVID-19 illness, the agency said.